‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales
Regeneron and Sanofi have opportunity to appeal or to reach resolution with Amgen after district judge delays imposition of permanent injunction for 30 days in PCSK9 patent case.
You may also be interested in...
While sales of Sanofi/Regeneron's Praluent, which will remain on the US market for the time being, could see a small boost, larger commercial challenges in the PCSK9 category linger.
Sanofi's CEO Olivier Brandicourt's reassuring 2017 guidance relies on continued cost savings, a successful launch of its Dupixent biologic, and winning a US legal case that threatens its PCSK9 inhibitor Praluent.
Acquisition strategy will likely be a prime focus as Gilead, Allergan, Sanofi and others face investors, especially in the wake of Johnson & Johnson’s buy-out of Actelion, ‘the one that got away’ from Sanofi.